Just more than a quarter of people have heard of the term 'personalized medicine,' according to a recent survey conducted by GfK Bridgehead, a market research firm. Additionally, as Ed Silverman at Pharmalot notes, many people think that such tailored treatments will lead to a rise in healthcare costs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

The Lobby Effect

CRO Future

Sorta Safe and Secure

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.